Crossmark

A New Era in the Treatment of Myasthenia Gravis: Six New Medications in The Last 6 Years

Published Online: 2024-01-23

Published Print: 2024-04

Authors

Patel, Ashish D.

Shah, Aashin

Avila, J. David https://orcid.org/0000-0001-8671-671X
License Information

Text and Data Mining valid from 2024-01-23

Version of Record valid from 2024-01-23
More Information

Article History

Accepted: 3 January 2024

First Online: 23 January 2024

Declarations

:

: A.D.P. has no competing financial and/or non-financial interests. A.S. has no competing financial and/or non-financial interests. J.D.A. has served on advisory boards for Alnylam Pharmaceuticals and Alexion. J.D.A. has received speaker honoraria from Alnylam Pharmaceuticals, argenx, Alexion and UCB.

Document is current